Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.
Approval Alert | Adagrasib for KRAS G12C–Mutated NSCLC
Patients with KRAS G12C–mutated non–small cell lung cancer can now receive adagrasib therapy following the treatment’s recent accelerated approval by the FDA.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
FDA Accepts NDA for New Nilotinib Formulation in CML
5
